Heterocyclic compounds and their preparation and use
AssigneeNovo Nordisk A/S
InventorsPeter Faarup, Palle Jakobsen, Anker Steen J.o slashed.rgensen, Henrik Klitgaard
Life of this patent
Estimating the term…
Abstract
The present invention relates to 9H-indeno[1,2-b]pyrazin-3(4H)-ones and 9H-indeno[1,2-b]pyrazine-2,3(1H,4H)-diones or tautomeric forms thereof which are useful in treating neurological and psychiatric diseases based on the antagonism of the glycine binding site on the NMDA receptor complex.
Claims29
A compound of formula (I) or a tautomeric form thereof ##STR24## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently are hydrogen, halogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy;
- and
- R.sup.5 is hydrogen;
- hydroxy;
- halogen;
- cyano;
- C.sub.1-6 -alkyl optionally substituted with hydroxy;
- C.sub.1-6 -alkoxy optionally substituted with one or two phenyl group(s) wherein the phenyl group(s) is/are optionally substituted with halogen;
- C.sub.1-6 -(alkoxyalkoxy);
- C.sub.1-6 -thioalkyl optionally substituted with an amino group wherein the amino group is optionally mono or disubstituted with C.sub.1-6 -alkyl;
- C.sub.1-6 -acyloxy;
- phosphono;
- C.sub.1-6 -alkoxy disubstituted phosphonyl;
- or a morpholino or piperazinyl group which is optionally substituted with a C.sub.1-6 -alkyl group wherein the alkyl group is optionally substituted by hydroxy or wherein the morpholino or piperazinyl group is optionally substituted with one or two phenyl group(s) wherein the phenyl group(s) is/are optionally substituted with methoxy;
- and R.sup.6 is hydrogen, C.sub.-6 -alkyl or phenyl;
- or R.sup.5 and R.sup.6 together represent a carbonyl group, a hydroxyimino group or a benzyloxyimino group;
- or
- a pharmaceutically acceptable salt thereof.
A compound of formula (I) or a tautomeric form thereof ##STR25## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently are hydrogen, halogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy;
- R.sup.5 is hydrogen;
- hydroxy;
- halogen;
- cyano;
- C.sub.1-6 -alkyl optionally substituted with hydroxy;
- C.sub.1-6 -alkoxy optionally substituted with one or two phenyl group(s) wherein the phenyl group(s) is/are optionally substituted with halogen;
- C.sub.1-6 -(alkoxyalkoxy);
- C.sub.1-6 -thioalkyl optionally substituted with an amino group wherein the amino group is optionally mono or disubstituted with C.sub.1-6 -alkyl;
- C.sub.1-6 -acyloxy;
- phosphono;
- C.sub.1-6 -alkoxy disubstituted phosphonyl;
- or a morpholino or piperazinyl group which is optionally substituted with a C.sub.1-6 -alkyl group wherein the alkyl group is optionally substituted by hydroxy or wherein the morpholino or piperazinyl group is optionally substituted with one or two phenyl group(s) wherein the phenyl group(s) is/are optionally substituted with methoxy;
- and R.sup.6 is hydrogen, C.sub.1-6 -alkyl or phenyl;
- or R.sup.5 and R.sup.6 together represent a carbonyl group, a hydroxyimino group or a benzyloxyimino group;
- and
- R.sup.7 is phenyl or --CH.sub.2 OR.sup.8 wherein R.sup.8 is hydrogen or benzyl;
- or
- a pharmaceutically acceptable salt thereof.
A method of treating a central nervous system ailment related to the glycine binding site on the NMDA receptor complex comprising administering to a subject in need thereof an effective amount of a compound of formula I or a tautomeric form thereof selected from the group consisting of ##STR26## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently are hydrogen, halogen, C.sub.1-6 -alkyl or C.sub.1-6 -alkoxy;
- R.sup.5 is hydrogen;
- hydroxy;
- halogen;
- cyano;
- C.sub.1-6 -alkyl optionally substituted with hydroxy;
- C.sub.1-6 -alkoxy optionally substituted with one or two phenyl group(s) wherein said phenyl group(s) is/are optionally substituted with halogen;
- C.sub.1-6 -(alkoxyalkoxy);
- C.sub.1-6 -thioalkyl optionally substituted with an amino group wherein said amino group is optionally mono or disubstituted with C.sub.1-6 -alkyl;
- C.sub.1-6 -acyloxy;
- phosphono;
- C.sub.1-6 -alkoxy disubstituted phosphonyl;, or a morpholina or piperazinyl group which is optionally substituted with a C.sub.1-6 -alkyl group wherein said alkyl group is optionally substituted by hydroxy or wherein the morphalina or piperazinyl group is optionally substituted with one or two phenyl group(s) wherein said phenyl group(s) is/are optionally substituted with methoxy;
- and R.sup.6 is hydrogen, C.sub.1-6 -alkyl or phenyl;
- or R.sup.5 and R.sup.6 together represent a carbonyl group, a hydroxyimino group or a benzyloxyimino group;
- and
- R.sup.7 is hydrogen, phenyl or --CH.sub.2 OR.sup.8 wherein R.sup.8 is hydrogen or benzyl;
- or
- a pharmaceutically acceptable salt thereof.
A compound which is:
- 9-Hydroxyimino-9H-indeno[1,2-b]pyrazin-3(4H)-one;
- 9-Chloro-9H-indeno[1,2-b]pyrazine-3(4H)-one;
- 9-Hydroxy-9H-indeno[1,2-b]pyrazine-3(4H)- one;
- 9-Hydroxy-9-phenyl-9H-indeno[1,2-b]pyrazine-3(4H)-one;
- 9-Acetoxy-9-phenyl-9H-indeno[1,2-b]pyrazine-3(4H)-one;
- or
- a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.